Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor

NCT02426086 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT02426086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02426086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
Lead sponsor
Geron Corporation
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2015
Completion date
February 7, 2020
Enrollment
107 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis